Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population-based cohort study

Cancer

Volumn 115, Issue 19, 2009, Pages 4442-4449

  Hernandez, Rohini K ^a   Sørensen, Henrik Toft ^a,b   Pedersen, Lars ^b   Jacobsen, Jacob ^b   Lash, Timothy L ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Deep venous thrombosis; Pulmonary embolism; Tamoxifen; Venous thromboembolism

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; DATA BASE; DEEP VEIN THROMBOSIS; FEMALE; HEALTH HAZARD; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; VENOUS THROMBOSIS;

EID: 70349288386     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24508     Document Type: Article

References (21)

1. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001;106:6-12.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
3. Ragaz J, Coldman C. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018-2024. (Pubitemid 28265035)
4. Goldhaber SZ. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation. 2005;111:539-541.
5. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282. (Pubitemid 47073490)
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388. (Pubitemid 28439961)
7. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 suppl 1):I17-I21. (Pubitemid 41289267)
8. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650-656. (Pubitemid 40216494)
9. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824. (Pubitemid 35257944)
10. Frank L. When an entire country is a cohort. Science. 2000; 287:2398-2399.
11. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
12. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773-1779. (Pubitemid 350137491)
13. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401-410.
14. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358:1037-1052.
15. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-780.
16. Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363:1295-1305.
17. Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003;21:3588-3593. (Pubitemid 46594050)
18. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092. (Pubitemid 38298988)
19. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619-629. (Pubitemid 46224240)
20. NCCN Practice Guidelines in Oncology, Breast Cancer. Invasive breast cancer, adjuvant endocrine therapy. Version 2.2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf Accessed January 29, 2008.
21. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133-1144.